Neoleukin Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Neurogene

25/02/2023 03:08

* Neoleukin Therapeutics Inc  NLTX.OQ   NLTX.O  is expected
to show no change in quarterly revenue when it reports 
results on February 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Neoleukin
Therapeutics
Inc is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $1​, above​ its last closing price of $0.51.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.30       -0.30      -0.24     Beat    21.1
 Jun. 30 2022  -0.30       -0.30      -0.28     Beat    6.7
 Mar. 31 2022  -0.27       -0.30      -0.28     Beat    5.6​
 Dec. 31 2021  -0.30       -0.30      -0.28     Beat    6.9
 ​​Sep.        -0.28       -0.28      -0.28     Met     -0.6
 30 2021                                                
 Jun. 30 2021  -0.27       -0.26      -0.27     Missed  -3.1​
 Mar. 31 2021  -0.23       -0.23      -0.27     Missed  -18.4
 Dec. 31 2020  -0.19       -0.25      -0.24     Beat    4.6
 This summary was machine generated February 25 at 03:08 GMT. 
All figures in US dollars  unless otherwise stated